2025-04-01 - Analysis Report
## Recursion Pharmaceuticals Inc (RXRX) Stock Review

**0. Key Figures:**

* **RXRX Cumulative Return:** -54.37%
* **VOO (S&P 500) Cumulative Return:** 22.08%
* **RXRX vs VOO Return Difference:** -76.5%
* **Relative Performance Rank:** 8.1% (Indicates RXRX underperformed VOO significantly, but not at its worst historical point)
* **Current Closing Price:** $5.97
* **Last Market Price:** $5.315 (a drop of -8.52%)


**1. Company Overview and Performance Comparison:**

Recursion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company leveraging AI and automation to discover and develop novel drugs.  The company's significant underperformance (-76.5%) compared to the S&P 500 (VOO) over the analyzed period is striking.  The provided Alpha and Beta analysis shows consistently negative alpha, indicating underperformance relative to the market, and a high Beta (2.1 to 3.5), reflecting significantly higher volatility than the market. The CAGR is also negative over all periods, highlighting poor long-term growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | -9.0% | 47.3% | -11.0% | 3.5 |  |
| 2022-2024  | 2.0% | 64.0% | -20.0% | 2.4 |  |
| 2023-2025  | -13.0% | 64.0% | -55.0% | 2.1 |  |


**2. Recent Price Movements:**

* **Closing Price:** $5.97
* **Last Market Price:** $5.315
* **5-Day Moving Average:** $6.43
* **20-Day Moving Average:** $6.45
* **60-Day Moving Average:** $7.33

The stock price is currently trading below all three moving averages, suggesting a bearish trend. The recent drop of -8.52% from the previous close is significant and needs further investigation.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4283 (Medium Risk)
* **RSI:** 41.48 (Below 50, suggesting bearish momentum)
* **PPO:** -0.0598 (Negative, indicating bearish momentum)
* **20-Day Relative Divergence Change:** -4.6% (Short-term downtrend)
* **Expected Return:** -267.0% (This extremely negative projected return compared to S&P500 over the long term raises significant concerns.)

The technical indicators point towards a bearish outlook.  The large negative expected return and significant recent price drop (-8.52%) highlight substantial downside risk.  This suggests the market is pricing in negative expectations for the company's future performance.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -0.34  | $0.03 B      |
| 2024-08-08 | -0.40  | $0.01 B      |
| 2024-05-09 | -0.39  | $0.01 B      |
| 2023-11-09 | -0.43  | $0.01 B      |
| 2024-11-06 | -0.43  | $0.01 B      | *(Duplicate Entry)*


Recurring losses (negative EPS) are evident, though there's some fluctuation in revenue.  The significant negative EPS and low revenue raise substantial concerns about the company's financial health and profitability.  The duplicate entry for 2024-11-06 needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B  | -183.62%     |
| 2024-09-30 | $0.03B  | 53.69%       |
| 2024-06-30 | $0.01B  | 36.14%       |
| 2024-03-31 | $0.01B  | 17.23%       |
| 2023-12-31 | $0.01B  | 6.99%        |

**Capital and Profitability:**

| Quarter | Equity  | ROE          |
|---------|---------|--------------|
| 2024-12-31 | $1.03B | -17.29%      |
| 2024-09-30 | $0.52B | -18.27%      |
| 2024-06-30 | $0.58B | -16.69%      |
| 2024-03-31 | $0.40B | -22.78%      |
| 2023-12-31 | $0.46B | -20.07%      |

The financial data reveals significant issues.  Negative profit margins and negative return on equity (ROE) across multiple quarters indicate severe financial distress.  The substantial fluctuation in equity also warrants further investigation. The dramatic swing from a negative to positive profit margin in Q3 2024  requires closer examination of the underlying drivers of this apparent improvement.  Overall, the financial picture is very concerning.

**6.  Overall Analysis:**

Recursion Pharmaceuticals (RXRX) shows extremely poor performance relative to the S&P 500, exhibiting consistent negative returns, high volatility, and significant financial distress as evidenced by negative profit margins and ROE.  Technical indicators suggest a bearish trend.  The extremely negative projected long-term return further reinforces the pessimistic outlook.  Given the current data, RXRX presents significant investment risk.  A more in-depth analysis of the recent Q3 2024 revenue surge and the reasons for consistently negative profitability would be crucial before making any investment decisions.  The information provided suggests a high probability of further price declines.  Any investment should be approached with extreme caution.
